» Articles » PMID: 14616929

The Effect of Nitric Oxide Synthase Inhibition on Histamine Induced Headache and Arterial Dilatation in Migraineurs

Overview
Journal Cephalalgia
Specialties Neurology
Psychiatry
Date 2003 Nov 18
PMID 14616929
Citations 25
Authors
Affiliations
Soon will be listed here.
Abstract

We have previously proposed that histamine causes migraine via increased NO production. To test this hypothesis, we here examined if the NOS inhibitor, L-NG methylarginine hydrochloride (L-NMMA:546C88), could block or attenuate histamine induced migraine attacks and responses of the middle cerebral, temporal and radial arteries. In a double blind crossover design 12 patients were randomized to receive pretreatment with L-NMMA (6 mg/kg) or placebo i.v. over 15 min followed on both study days by histamine (0.5 microg/kg/min) i.v. for 20 min. Headache scores, mean maximal blood velocity (Vmean) in the middle cerebral artery (MCA) (transcranial doppler) and diameters of temporal and radial arteries (high resolution ultrasound) were repeatedly measured. Pre-treatment with L-NMMA, had no effect on histamine induced headache or migraine, but also had no effect on the magnitude of histamine induced-decrease in MCA blood velocity, or dilatation of neither the temporal nor the radial artery. L-NMMA constricted the temporal artery by 8% before histamine infusion, whereas the radial artery was unaffected. The temporal artery dilated 4-5 times more than the radial artery during histamine infusion. In conclusion the use of a NOS inhibitor in the highest possible dose did not block the histamine-induced headache response or arterial dilatation. Either the concentration of L-NMMA reaching the smooth muscle cell was insufficient or, histamine dilates arteries and causes headache via NO independent mechanisms. Our results showed for the first time a craniospecificity for the vasodilating effect of histamine and for the arterial effects of NOS inhibition.

Citing Articles

Provocation of attacks to discover migraine signaling mechanisms and new drug targets: early history and future perspectives - a narrative review.

Olesen J J Headache Pain. 2024; 25(1):105.

PMID: 38902612 PMC: 11188241. DOI: 10.1186/s10194-024-01796-1.


Neuropeptides and the Nodes of Ranvier in Cranial Headaches.

Edvinsson J, Haanes K, Edvinsson L Front Physiol. 2022; 12:820037.

PMID: 35095575 PMC: 8791651. DOI: 10.3389/fphys.2021.820037.


Nitric oxide synthase inhibition in healthy adults reduces regional and total cerebral macrovascular blood flow and microvascular perfusion.

Carter K, Ward A, Kellawan J, Eldridge M, Al-Subu A, Walker B J Physiol. 2021; 599(22):4973-4989.

PMID: 34587648 PMC: 9009720. DOI: 10.1113/JP281975.


The association between dietary tryptophan intake and migraine.

Jahromi S, Togha M, Ghorbani Z, Hekmatdoost A, Khorsha F, Rafiee P Neurol Sci. 2019; 40(11):2349-2355.

PMID: 31254181 DOI: 10.1007/s10072-019-03984-3.


CSD-Induced Arterial Dilatation and Plasma Protein Extravasation Are Unaffected by Fremanezumab: Implications for CGRP's Role in Migraine with Aura.

Schain A, Melo-Carrillo A, Stratton J, Strassman A, Burstein R J Neurosci. 2019; 39(30):6001-6011.

PMID: 31127003 PMC: 6650995. DOI: 10.1523/JNEUROSCI.0232-19.2019.